Impact of the COVID-19 Pandemic on Vaccination

Covid19 Clinical Trial

— COVIDVacImpac  

Official title:

Impact of the COVID-19 Pandemic on Vaccination in Patients at Risk of Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04657263
• Other study ID #: RECHMPL20_0655
• Status: Completed
• Start date: November 1, 2020
• Est. completion date: May 30, 2021

Study information

• Verified date: October 2021
• Source: University Hospital, Montpellier
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The vaccination policy is drawn up in France by the French Minister of Health, who makes public the vaccination schedule after the opinion of the High Authority of Health.

Currently according to the 2019 immunization schedule, the dTP vaccine is the only mandatory in the general population with recalls in adults aged 25, 45, 65 and every 10 years. In 2011, the Ministry of Health estimated that only 50.5% of the general population was up to date against dTP.

Two vaccines are recommended for person at risk of infection according to the current vaccine schedule: the flu vaccine and the pneumococcal vaccine. In fact, influenza and pneumococcal disease are more frequent and more serious in patients with chronic diseases (diabetes, cardiac insufficiency..) compared to the general population.

The vaccination coverage rate of at-risk populations is dramatically below the vaccination coverage targets set by the Ministry of Health. Indeed, there are many barriers to vaccination, medical and para-medical barriers, but also individual barriers.

The current COVID-19 pandemic has identified people at risk of severe infection and death risk, particularly those with co-morbidities (diabetes, cardiovascular disease, etc.). Thus, this pandemic may have contributed to change in patients' perceptions regarding both the risk of infection and the potential interest and benefit of vaccination.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 500
• Est. completion date: May 30, 2021
• Est. primary completion date: May 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Person at risk of infection according to french 2019 immunization schedule

• Patients aged above 18 years old

Exclusion criteria:

• Patient < 18 years

Related Conditions & MeSH terms

• COVID-19
• Covid19

Intervention

Other:
• Vaccine coverage assessment
Vaccine coverage assessment

Locations

Country	Name	City	State
France	Uhmontpellier	Montpellier

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of persons at risk of infection up to date with their mandatory and recommended vaccinations during COVID19 pandemic	number of persons at risk of infection up to date with their mandatory and recommended vaccinations during COVID19 pandemic	1 day
Secondary	Number of persons at risk of infection accepting COVID19 vaccination	Number of persons at risk of infection accepting COVID19 vaccination	1 day